1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:CCT definition of success at 5–7 months
Angiographic Occlusion at First Follow-Up AcomA Aneurysm A1 Co-Dominant (n = 31), No. (%) AcomA Aneurysm A1 Dominant (n = 86), No. (%) Complete 13 (42%) 29 (34%) Stable 0 (0%) 3 (3%) Improved 6 (19%) 17 (20%) Totala 19 (61%) 49 (57%)
↵a There were 12 (39%) and 37 (43%) from each group that did not meet the CCT definition of success at 5–7 month follow-up.